Anti-Cancer Discovery & Therapy (Track)


Katarzyna Kempińska, Elżbieta Pajtasz-Piasecka, Anna Nasulewicz-Goldeman, Czesław Ługowski, Janusz Boratyński and Joanna Wietrzyk 

Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Science, Poland


Lipopolysacharides (LPS) could regress tumor growth in animal cancer models, which occurs to be promising for cancer immunotherapy. However, its use in human cancer therapy has been limited only to one trial, since is toxic causing sepsis. Numerous peptides have been designed to bind and neutralize LPS. One of them is a peptide polymyxin B which prevents noxious LPS effects occurrence during LPS-mediated endotoxin shock in animal models. In order to obtain the anticancer effect of LPS avoiding its toxicity we investigated the influence of LPS complexes with polymyxin and LPS complexes with anti-LPS antibody on lung metastases formation in the mice bearing B16 melanoma. In mice treated with both LPS complexes the number of metastatic foci was approximately 50-70% lower in comparison to control group of mice.

This work was supported by Polish Ministry of Science and Higher Education -The National Centre for Research and Development (NCBiR) NR 13 0089 06 "Products of cell lysis of Gram negative bacteria".

Keywords: Melanoma, polymyxin B, lipopolysacharides.